Sanofi | CIK:0001121404 | 3

  • Filed: 3/16/2018
  • Entity registrant name: Sanofi (CIK: 0001121404)
  • Generator: Donnelley Financial Solutions
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1121404/000119312518084834/0001193125-18-084834-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1121404/000119312518084834/sny-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001121404
  • Open this page in separate window: Click
  • ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory

    B.17. Amortization and impairment of intangible assets

    B.17.1. Amortization of intangible assets

    The expenses recorded in this line item comprise amortization of product rights (see Note D.4.), given that the benefit of those rights to Sanofi’s commercial, industrial and development functions cannot be separately identified.

    Amortization of software, and of other rights of an industrial or operational nature, is recognized as an expense in the income statement, in the relevant line items of expense by function.

    B.17.2. Impairment of intangible assets

    This line item records impairment losses (other than those associated with restructuring) recognized against intangible assets (including goodwill, but excluding software and other rights of an industrial or operational nature), and any reversals of such impairment losses.